The Effects of Breathing Retraining in Patients With Interstitial Lung Diseases

Interstitial Lung Disease Clinical Trial

Official title:

The Effects of Breathing Retraining on Dyspnoea Measures and the Six-Minute Walking Distance in Patients With Interstitial Lung Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03729583
• Other study ID #: MAxiak
• Status: Completed
• Phase: N/A
• Start date: July 1, 2017
• Est. completion date: May 18, 2018

Study information

• Verified date: November 2018
• Source: University of Malta
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Breathing retraining has been reported to lead to improvements in dyspnoea and walking distance in chronic obstructive pulmonary disease (COPD) patients. Evidence regarding the effects of such an intervention in ILD patients is though lacking. In view of this, the aims of such a study were to identify whether breathing retraining led to better management of dyspnoea and improved walking distance in ILD patients.

Description:

One of the commonest symptoms experienced in patients with a diagnosis of interstitial lung disease (ILD) is shortness of breath, a symptom which greatly affects their abilities to carry out activities of daily living. Breathing retraining has been reported to lead to improvements in dyspnoea and walking distance in chronic obstructive pulmonary disease (COPD) patients. Evidence regarding the effects of such an intervention in ILD patients is though lacking. In view of this, the aims of such a study were to identify whether breathing retraining led to better management of dyspnoea and improved walking distance in ILD patients. Twenty Seven ILD patients were randomly distributed to either the control group (n=15) which received a 12-week Pulmonary Rehabilitation (PR) programme without breathing retraining or the active group (n=12) which received a 12-week PR programme with breathing retraining. All patients had both the 6-minute walk test and their level of breathlessness assessed using the Dyspnoea Borg scale assessed at baseline and at 4 weekly intervals for a 12-week period throughout the programme.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: May 18, 2018
• Est. primary completion date: November 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with a confirmed diagnosis of ILD and who were referred for PR

Exclusion Criteria:

• Patients who had musculoskeletal or neurological conditions affecting the outcome measures

• Patients who required oxygen therapy and did not accept administration

• Patients with unstable cardiovascular conditions

• Patients who were not willing to participate

Related Conditions & MeSH terms

• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial

Intervention

Behavioral:
• Pulmonary Rehabilitation
A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises

Locations

Country	Name	City	State
Malta	Melanie Axiak	Mosta

Sponsors (1)

Lead Sponsor	Collaborator
University of Malta

Country where clinical trial is conducted

Malta, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	6 minute walk test	A walk test to examine exercise endurance	Change in walking distance from baseline to 12weeks
Secondary	Dyspnoea score	Borg scale	Change in dyspnoea measures from baseline to 12weeks